Why is SPARC falling/rising?

As of 03-Jul, Sun Pharma Advanced Research Company Ltd is experiencing a decline in its stock price, currently at 159.40, which reflects a decrease of 0.8 or 0.5%. The stock has underperformed its sector by 0.98% today and has been on a consecutive downward trend for the last three days, resulting in a total return drop of 2.03% during this period. Over the past month, the stock has significantly underperformed, with a return of -18.51%, while the benchmark Sensex has gained 3.10%. The company is facing challenges, including a negative book value and weak long-term fundamental strength, as evidenced by a decline in net sales and operating profit over the last five years. Additionally, the stock's liquidity is adequate for trading, but there has been a notable drop in investor participation, with delivery volume falling by 28.8% against the five-day average.
In the broader market context, the stock's performance has been consistently poor compared to the benchmark, with a year-to-date return of -20.40% against the Sensex's gain of 6.53%. This consistent underperformance is highlighted by the stock's returns over the last three years, where it has lagged behind the BSE500. The negative EBITDA and weak ability to service debt further contribute to the stock's risk profile, making it less attractive to investors. Overall, the combination of poor financial metrics, declining investor interest, and significant underperformance relative to the market has led to the stock's current downward trajectory.